Nordic Issuing

Ongoing case

Diagonal Bio AB

Back to all cases

Diagonal Bio AB

10 Jun - 24 Jun 2021IPO

Diagonal Bio AB (formerly Diagonal Pharma AB) is a Swedish biotech company founded in 2020 with headquarters and offices in Lund. The company is developing the Panviral platform to detect and diagnose small sections of pathogen genomes – such as viruses, bacteria and fungi.

The company was founded with the goal of reducing human suffering by revolutionizing global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal is one of the few players globally that enables testing of several pathogens simultaneously. Customers – which can comprise everything from, for example, healthcare facilities to airports and research institutes – receive a complete tool that can easily be integrated into existing operations.

Read more on the company's website

The offer in summary

Subscription period: 10 June - 24 June 2021

Subscription price: 10,50 SEK per share

Minimum acquisition : 570 shares, corresponding to 5,985.00 SEK

Valuation (pre-money) : Circa 56 MSEK

Volume of issuance: The offer comprises a maximum of 3 814 663 shares

Listing on Nasdaq First North Growth Market: 6 July 2021

Those who have registered via Nordnet or Avanza will be notified of the allotment by booking the allotted number of shares against payment of cash in the specified account. This is expected to take place on 30 June. Please note that cash for the payment of allotted shares must be available from 24 June 2021 until 2 July 2021.


  Prospectus (swedish)



Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.